Live Feeds
● LIVE Updated 2h ago · 25 sources tracked

New mRNA Vaccine Reduces Risk of Melanoma Recurrence by Over 40 Percent

A personalized mRNA cancer vaccine called intismeran, developed by Moderna and Merck, cut the risk of melanoma recurrence or death by 42 percent when combined with standard immunotherapy. Results from the randomized phase 3 INTerpath-001 trial showed the bespoke treatment also lowered the risk of distant metastasis or death by 38 percent in patients with completely resected high-risk melanoma. The long-awaited findings were released by the pharmaceutical companies and scheduled for presentation at the ESMO Congress.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~3 min
Speed:
RSS Source map (25)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ The personalized mRNA vaccine, called intismeran, combined with standard adjuvant therapy reduced the risk of recurrence or death by 42 percent among patients with completely resected high-risk melanoma.
  • ✓ The combination treatment reduced the risk of distant metastasis or death by 38 percent.
  • ✓ The findings come from the randomized phase 3 INTerpath-001 trial conducted by Moderna and Merck.
🛡️ Source Corroboration: 25 independent reporting domains (100% confidence) ⏱ Read time: ~2 min

What changed

Phase 3 clinical trial results from the INTerpath-001 study were released, providing definitive statistical proof that the personalized mRNA vaccine reduces recurrence and death.

Live updates

  1. mRNA Vaccine Reduces Melanoma Recurrence Risk by 42 Percent

    A personalized mRNA cancer vaccine called intismeran, developed by Moderna and Merck, cut the risk of melanoma recurrence or death by 42 percent when combined with standard immunotherapy. Results from the randomized phase 3 INTerpath-001 trial showed the bespoke treatment also lowered the risk of distant metastasis or death by 38 percent in patients with completely resected high-risk melanoma. The long-awaited findings were released by the pharmaceutical companies and scheduled for presentation at the ESMO Congress.

    Why it matters

    The trial data marks a foundational shift in oncology by using messenger RNA technology to train a patient immune system against specific tumor mutations. Researchers and industry executives have hailed the results as a major advance for treating aggressive forms of skin cancer. The therapy works by creating a custom vaccine tailored to the unique biological signature of an individual tumor.

    What is confirmed

    • The personalized mRNA vaccine, called intismeran, combined with standard adjuvant therapy reduced the risk of recurrence or death by 42 percent among patients with completely resected high-risk melanoma.
    • The combination treatment reduced the risk of distant metastasis or death by 38 percent.
    • The findings come from the randomized phase 3 INTerpath-001 trial conducted by Moderna and Merck.

    Still unconfirmed

    • Data from the ESMO cancer vaccine presentation was subject to an unfortunate leak prior to the official conference release.

    What to watch next

    • The official presentation of the INTerpath-001 trial data at the ESMO Congress.
    • Regulatory submissions and discussions regarding patient access and treatment costs.
    Sources used for this update (26)
    1. www.wired.com — WIRED - The Latest in Technology, Science, Culture and Business
    2. www.merck.com — Merck | Home
    3. Ars Technica — Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%
    4. AP News — A novel mRNA cancer vaccine helps reduce the chances of melanoma patients' tumors returning
    5. The New York Times — Melanoma Vaccine Ushers in New Hope for Cancer Patients
    6. NBC News — Personalized mRNA vaccine for melanoma cut risk of cancer’s return in late-stage trial
    7. WSJ — Moderna Investors Should Brace for More Whiplash
    8. WIRED — New mRNA Vaccine Reduces Risk of Melanoma Recurrence by Over 40 Percent
    9. Fierce Biotech — ‘It is what it is’: Merck exec unruffled by ‘unfortunate’ leak of ESMO cancer vaccine data
    10. STAT — The ESMO presentation everyone’s been waiting for
    11. ABC News - Breaking News, Latest News and Videos — Breakthrough cancer vaccine reduces melanoma from returning by 42%, data shows
    12. Endpoints News — Merck and Moderna's cancer vaccine data were 'a triumph of science.' And now, the work begins
    confidence 100%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community